Review Papers
-
The expanding incretin universe: from basic biology to clinical translation (Drucker et al, Diabetologia 2023)
-
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins' (Skow et al, Diabetes Obes Metab 2016)
-
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
-
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
-
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Guidelines and Recommendations
-
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update (Diabetes Canada)
-
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update — The User’s Guide
-
Targets for Glycemic Control
-
Monitoring Glycemic Control
-
Weight Management in Diabetes
-
Blood Glucose Monitoring in Adults and Children with Diabetes: Update 2021
-
Special Article: Remission of Type 2 Diabetes
-
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Canadian Adult Obesity Clinical Practice Guidelines
Study Publications
-
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Rosenstock et al, Lancet. 2021)
-
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
-
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (Ludvik et al, Lancet 2021)
-
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
-
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (Del Prato et al, Lancet 2021)
-
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (Dahl et al, JAMA 2022)
-
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial
-
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
-
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial
-
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
-
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial
